Recent insights into the molecular mechanisms of the NLRP3 inflammasome activation.

F1000Research

Volumn 5, Issue , 2016, Pages

  Próchnicki, Tomasz ^a   Mangan, Matthew S ^a,c   Latz, Eicke ^a,b,c,d  

^a UNIVERSITY HOSPITAL BONN   (Germany)

^b UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^c GERMAN CENTER FOR NEURODEGENERATIVE DISEASES DZNE   (Germany)

^d NORWEGIAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM ION; CASPASE 11; CRYOPYRIN; CYCLIC AMP; CYSTEINE; INFLAMMASOME; POTASSIUM ION; PROTEIN NEK7; PROTEIN SERINE THREONINE KINASE; SULFONYLUREA; UNCLASSIFIED DRUG;

AUTOINFLAMMATORY DISEASE; AUTOPHAGY; CALCIUM TRANSPORT; HUMAN; IMMUNOMODULATION; INHIBITION KINETICS; MOLECULAR MODEL; NONHUMAN; POTASSIUM TRANSPORT; REGULATORY MECHANISM; REVIEW; SIGNAL TRANSDUCTION;

EID: 85010916994     PISSN: None     EISSN: 20461402     Source Type: Journal    
DOI: 10.12688/F1000RESEARCH.8614.1     Document Type: Review

References (90)

1. Perregaux D, Barberia J, Lanzetti AJ, et al.: IL-1 beta maturation: evidence that mature cytokine formation can be induced specifically by nigericin. J Immunol. 1992; 149(4): 1294-303.
2. Perregaux D, Gabel CA: Interleukin-1 beta maturation and release in response to ATP and nigericin. Evidence that potassium depletion mediated by these agents is a necessary and common feature of their activity. J Biol Chem. 1994; 269(21): 15195-203.
3. Walev I, Reske K, Palmer M, et al.: Potassium-inhibited processing of IL-1 beta in human monocytes. EMBO J. 1995; 14(8): 1607-14.
4. Mariathasan S, Weiss DS, Newton K, et al.: Cryopyrin activates the inflammasome in response to toxins and ATP. Nature. 2006; 440(7081): 228-32.
5. Muñoz-Planillo R, Kuffa P, Martínez-Colón G, et al.: K+ efflux is the common trigger of NLRP3 inflammasome activation by bacterial toxins and particulate matter. Immunity. 2013; 38(6): 1142-53.
6. Martinon F, Pétrilli V, Mayor A, et al.: Gout-associated uric acid crystals activate the NALP3 inflammasome. Nature. 2006; 440(7081): 237-41.
7. Hornung V, Bauernfeind F, Halle A, et al.: Silica crystals and aluminum salts activate the NALP3 inflammasome through phagosomal destabilization. Nat Immunol. 2008; 9(8): 847-56.
8. Wright SH: Generation of resting membrane potential. Adv Physiol Educ. 2004; 28(1-4): 139-42.
9. Niebur E: Electrical properties of cell membranes. Scholarpedia. 2008; 3(6): 7166.
10. Alves LA, de Melo Reis RA, de Souza CA, et al.: The P2X7 receptor: shifting from a low-to a high-conductance channel-an enigmatic phenomenon? Biochim Biophys Acta. 2014; 1838(10): 2578-87.
11. Kelkar DA, Chattopadhyay A: The gramicidin ion channel: a model membrane protein. Biochim Biophys Acta. 2007; 1768(9): 2011-25.
12. Pressman BC: Biological applications of ionophores. Annu Rev Biochem. 1976; 45: 501-30.
13. Deng D, Jiang N, Hao SJ, et al.: Loss of membrane cholesterol influences lysosomal permeability to potassium ions and protons. Biochim Biophys Acta. 2009; 1788(2): 470-6.
14. Schorn C, Frey B, Lauber K, et al.: Sodium overload and water influx activate the NALP3 inflammasome. J Biol Chem. 2011; 286(1): 35-41.
15. Churchill PC: Second messengers in renin secretion. Am J Physiol. 1985; 249(2 Pt 2): F175-84.
16. Compan V, Baroja-Mazo A, López-Castejón G, et al.: Cell volume regulation modulates NLRP3 inflammasome activation. Immunity. 2012; 37(3): 487-500.
17. Ordaz B, Tuz K, Ochoa LD, et al.: Osmolytes and mechanisms involved in regulatory volume decrease under conditions of sudden or gradual osmolarity decrease. Neurochem Res. 2004; 29(1): 65-72.
18. He Y, Zeng MY, Yang D, et al.: NEK7 is an essential mediator of NLRP3 activation downstream of potassium efflux. Nature. 2016; 530(7590): 354-7.
19. Schmid-Burgk JL, Chauhan D, Schmidt T, et al.: A Genome-wide CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats) Screen Identifies NEK7 as an Essential Component of NLRP3 Inflammasome Activation. J Biol Chem. 2016; 291(1): 103-9.
20. Shi H, Wang Y, Li X, et al.: NLRP3 activation and mitosis are mutually exclusive events coordinated by NEK7, a new inflammasome component. Nat Immunol. 2016; 17(3): 250-8.
21. Juliana C, Fernandes-Alnemri T, Kang S, et al.: Non-transcriptional priming and deubiquitination regulate NLRP3 inflammasome activation. J Biol Chem. 2012; 287(43): 36617-22.
22. Haq T, Richards MW, Burgess SG, et al.: Mechanistic basis of Nek7 activation through Nek9 binding and induced dimerization. Nat Commun. 2015; 6: 8771.
23. Broderick L, De Nardo D, Franklin BS, et al.: The inflammasomes and autoinflammatory syndromes. Annu Rev Pathol. 2015; 10: 395-424.
24. Shi J, Zhao Y, Wang Y, et al.: Inflammatory caspases are innate immune receptors for intracellular LPS. Nature. 2014; 514(7521): 187-92.
25. Kayagaki N, Warming S, Lamkanfi M, et al.: Non-canonical inflammasome activation targets caspase-11. Nature. 2011; 479(7371): 117-21.
26. Yang D, He Y, Muñoz-Planillo R, et al.: Caspase-11 Requires the Pannexin-1 Channel and the Purinergic P2X7 Pore to Mediate Pyroptosis and Endotoxic Shock. Immunity. 2015; 43(5): 923-32.
27. Schmid-Burgk JL, Gaidt MM, Schmidt T, et al.: Caspase-4 mediates noncanonical activation of the NLRP3 inflammasome in human myeloid cells. Eur J Immunol. 2015; 45(10): 2911-7.
28. Rühl S, Broz P: Caspase-11 activates a canonical NLRP3 inflammasome by promoting K+ efflux. Eur J Immunol. 2015; 45(10): 2927-36.
29. Pelegrin P, Surprenant A: Pannexin-1 mediates large pore formation and interleukin-1beta release by the ATP-gated P2X7 receptor. EMBO J. 2006; 25(21): 5071-82.
30. Bartlett R, Stokes L, Sluyter R: The P2X7 receptor channel: recent developments and the use of P2X7 antagonists in models of disease. Pharmacol Rev. 2014; 66(3): 638-75.
31. He W, Wan H, Hu L, et al.: Gasdermin D is an executor of pyroptosis and required for interleukin-1β secretion. Cell Res. 2015; 25(12): 1285-98.
32. Kayagaki N, Stowe IB, Lee BL, et al.: Caspase-11 cleaves gasdermin D for non-canonical inflammasome signalling. Nature. 2015; 526(7575): 666-71.
33. Shi J, Zhao Y, Wang K, et al.: Cleavage of GSDMD by inflammatory caspases determines pyroptotic cell death. Nature. 2015; 526(7575): 660-5.
34. Sanman LE, Qian Y, Eisele NA, et al.: Disruption of glycolytic flux is a signal for inflammasome signaling and pyroptotic cell death. eLife. 2016; 5: pii: e13663.
35. Heid ME, Keyel PA, Kamga C, et al.: Mitochondrial reactive oxygen species induces NLRP3-dependent lysosomal damage and inflammasome activation. J Immunol. 2013; 191(10): 5230-8.
36. Zhou R, Yazdi AS, Menu P, et al.: A role for mitochondria in NLRP3 inflammasome activation. Nature. 2011; 469(7329): 221-5.
37. Broz P, Newton K, Lamkanfi M, et al.: Redundant roles for inflammasome receptors NLRP3 and NLRC4 in host defense against Salmonella. J Exp Med. 2010; 207(8): 1745-55.
38. Moon JS, Hisata S, Park MA, et al.: mTORC1-Induced HK1-Dependent Glycolysis Regulates NLRP3 Inflammasome Activation. Cell Rep. 2015; 12(1): 102-15.
39. Gaidt MM, Ebert TS, Chauhan D, et al.: Human Monocytes Engage an Alternative Inflammasome Pathway. Immunity. 2016; 44(4): 833-46.
40. Murakami T, Ockinger J, Yu J, et al.: Critical role for calcium mobilization in activation of the NLRP3 inflammasome. Proc Natl Acad Sci U S A. 2012; 109(28): 11282-7.
41. Rossol M, Pierer M, Raulien N, et al.: Extracellular Ca2+ is a danger signal activating the NLRP3 inflammasome through G protein-coupled calcium sensing receptors. Nat Commun. 2012; 3: 1329.
42. Lee G, Subramanian N, Kim AI, et al.: The calcium-sensing receptor regulates the NLRP3 inflammasome through Ca2+ and cAMP. Nature. 2012; 492(7427): 123-7.
43. Clapham DE: Calcium signaling. Cell. 2007; 131(6): 1047-58.
44. Walsh C, Barrow S, Voronina S, et al.: Modulation of calcium signalling by mitochondria. Biochim Biophys Acta. 2009; 1787(11): 1374-82.
45. Bleasdale JE, Thakur NR, Gremban RS, et al.: Selective inhibition of receptorcoupled phospholipase C-dependent processes in human platelets and polymorphonuclear neutrophils. J Pharmacol Exp Ther. 1990; 255(2): 756-68.
46. Maruyama T, Kanaji T, Nakade S, et al.: 2APB, 2-aminoethoxydiphenyl borate, a membrane-penetrable modulator of Ins(1, 4, 5)P3-induced Ca2+ release. J Biochem. 1997; 122(3): 498-505.
47. Katsnelson MA, Rucker LG, Russo HM, et al.: K+ efflux agonists induce NLRP3 inflammasome activation independently of Ca2+ signaling. J Immunol. 2015; 194(8): 3937-52.
48. Rada B, Park JJ, Sil P, et al.: NLRP3 inflammasome activation and interleukin-1β release in macrophages require calcium but are independent of calciumactivated NADPH oxidases. Inflamm Res. 2014; 63(10): 821-30.
49. Menu P, Mayor A, Zhou R, et al.: ER stress activates the NLRP3 inflammasome via an UPR-independent pathway. Cell Death Dis. 2012; 3: e261.
50. Brough D, Le Feuvre RA, Wheeler RD, et al.: Ca2+ stores and Ca2+ entry differentially contribute to the release of IL-1 beta and IL-1 alpha from murine macrophages. J Immunol. 2003; 170(6): 3029-36.
51. Okada M, Matsuzawa A, Yoshimura A, et al.: The lysosome rupture-activated TAK1-JNK pathway regulates NLRP3 inflammasome activation. J Biol Chem. 2014; 289(47): 32926-36.
52. Yaron JR, Gangaraju S, Rao MY, et al.: K+ regulates Ca2+ to drive inflammasome signaling: dynamic visualization of ion flux in live cells. Cell Death Dis. 2015; 6: e1954.
53. Saoudi Y, Rousseau B, Doussière J, et al.: Calcium-independent cytoskeleton disassembly induced by BAPTA. Eur J Biochem. 2004; 271(15): 3255-64.
54. Erb L, Weisman GA: Coupling of P2Y receptors to G proteins and other signaling pathways. Wiley Interdiscip Rev Membr Transp Signal. 2012; 1(6): 789-803.
55. Triantafilou K, Hughes TR, Triantafilou M, et al.: The complement membrane attack complex triggers intracellular Ca2+ fluxes leading to NLRP3 inflammasome activation. J Cell Sci. 2013; 126(Pt 13): 2903-13.
56. Rimessi A, Bezzerri V, Patergnani S, et al.: Mitochondrial Ca2+-dependent NLRP3 activation exacerbates the Pseudomonas aeruginosa-driven inflammatory response in cystic fibrosis. Nat Commun. 2015; 6: 6201.
57. Yu J, Nagasu H, Murakami T, et al.: Inflammasome activation leads to Caspase-1-dependent mitochondrial damage and block of mitophagy. Proc Natl Acad Sci U S A. 2014; 111(43): 15514-9.
58. Brennan SC, Thiem U, Roth S, et al.: Calcium sensing receptor signalling in physiology and cancer. Biochim Biophys Acta. 2013; 1833(7): 1732-44.
59. Sokolowska M, Chen L, Liu Y, et al.: Prostaglandin E2 Inhibits NLRP3 Inflammasome Activation through EP4 Receptor and Intracellular Cyclic AMP in Human Macrophages. J Immunol. 2015; 194(11): 5472-87.
60. Yan Y, Jiang W, Liu L, et al.: Dopamine controls systemic inflammation through inhibition of NLRP3 inflammasome. Cell. 2015; 160(1-2): 62-73.
61. Bitterman JL, Ramos-Espiritu L, Diaz A, et al.: Pharmacological distinction between soluble and transmembrane adenylyl cyclases. J Pharmacol Exp Ther. 2013; 347(3): 589-98.
62. Rehmann H, Wittinghofer A, Bos JL: Capturing cyclic nucleotides in action: snapshots from crystallographic studies. Nat Rev Mol Cell Biol. 2007; 8(1): 63-73.
63. Gribble FM, Loussouarn G, Tucker SJ, et al.: A novel method for measurement of submembrane ATP concentration. J Biol Chem. 2000; 275(39): 30046-9.
64. Larcombe-McDouall J, Buttell N, Harrison N, et al.: In vivo pH and metabolite changes during a single contraction in rat uterine smooth muscle. J Physiol. 1999; 518(Pt 3): 783-90.
65. Iancu RV, Ramamurthy G, Warrier S, et al.: Cytoplasmic cAMP concentrations in intact cardiac myocytes. Am J Physiol Cell Physiol. 2008; 295(2): C414-22.
66. Rahman N, Buck J, Levin LR: pH sensing via bicarbonate-regulated "soluble" adenylyl cyclase (sAC). Front Physiol. 2013; 4: 343.
67. Harris J, Hartman M, Roche C, et al.: Autophagy controls IL-1beta secretion by targeting pro-IL-1beta for degradation. J Biol Chem. 2011; 286(11): 9587-97.
68. Nakahira K, Haspel JA, Rathinam VAK, et al.: Autophagy proteins regulate innate immune responses by inhibiting the release of mitochondrial DNA mediated by the NALP3 inflammasome. Nat Immunol. 2011; 12(3): 222-30.
69. Lupfer C, Thomas PG, Anand PK, et al.: Receptor interacting protein kinase 2-mediated mitophagy regulates inflammasome activation during virus infection. Nat Immunol. 2013; 14(5): 480-8.
70. Wen H, Gris D, Lei Y, et al.: Fatty acid-induced NLRP3-ASC inflammasome activation interferes with insulin signaling. Nat Immunol. 2011; 12(5): 408-15.
71. Shi C, Shenderov K, Huang N, et al.: Activation of autophagy by inflammatory signals limits IL-1β production by targeting ubiquitinated inflammasomes for destruction. Nat Immunol. 2012; 13(3): 255-63.
72. Zhong Z, Umemura A, Sanchez-Lopez E, et al.: NF-κB Restricts Inflammasome Activation via Elimination of Damaged Mitochondria. Cell. 2016; 164(5): 896-910.
73. Perregaux DG, McNiff P, Laliberte R, et al.: Identification and characterization of a novel class of interleukin-1 post-translational processing inhibitors. J Pharmacol Exp Ther. 2001; 299(1): 187-97.
74. Lamkanfi M, Mueller JL, Vitari AC, et al.: Glyburide inhibits the Cryopyrin/Nalp3 inflammasome. J Cell Biol. 2009; 187(1): 61-70.
75. Coll RC, Robertson AAB, Chae JJ, et al.: A small-molecule inhibitor of the NLRP3 inflammasome for the treatment of inflammatory diseases. Nat Med. 2015; 21(3): 248-55.
76. Liao J, Kapadia VS, Brown LS, et al.: The NLRP3 inflammasome is critically involved in the development of bronchopulmonary dysplasia. Nat Commun. 2015; 6: 8977.
77. Krishnan SM, Dowling JK, Ling YH, et al.: Inflammasome activity is essential for one kidney/deoxycorticosterone acetate/salt-induced hypertension in mice. Br J Pharmacol. 2016; 173(4): 752-65.
78. Hughes FM, Hill HM, Wood CM, et al.: The NLRP3 Inflammasome Mediates Inflammation Produced by Bladder Outlet Obstruction. J Urol. 2016; 195(5): 1598-605.
79. York JM, Castellanos KJ, Cabay RJ, et al.: Inhibition of the nucleotidebinding domain, leucine-rich containing family, pyrin-domain containing 3 inflammasome reduces the severity of experimentally induced acute pancreatitis in obese mice. Transl Res. 2014; 164(4): 259-69.
80. Trube G, Rorsman P, Ohno-Shosaku T: Opposite effects of tolbutamide and diazoxide on the ATP-dependent K+ channel in mouse pancreatic beta-cells. Pflugers Arch. 1986; 407(5): 493-9.
81. Sturgess NC, Ashford ML, Cook DL, et al.: The sulphonylurea receptor may be an ATP-sensitive potassium channel. Lancet. 1985; 2(8453): 474-5.
82. Henquin JC: Tolbutamide stimulation and inhibition of insulin release: studies of the underlying ionic mechanisms in isolated rat islets. Diabetologia. 1980; 18(2): 151-60.
83. Laliberte RE, Perregaux DG, Hoth LR, et al.: Glutathione s-transferase omega 1-1 is a target of cytokine release inhibitory drugs and may be responsible for their effect on interleukin-1beta posttranslational processing. J Biol Chem. 2003; 278(19): 16567-78.
84. He Y, Varadarajan S, Muñoz-Planillo R, et al.: 3, 4-methylenedioxy-β-nitrostyrene inhibits NLRP3 inflammasome activation by blocking assembly of the inflammasome. J Biol Chem. 2014; 289(2): 1142-50.
85. Juliana C, Fernandes-Alnemri T, Wu J, et al.: Anti-inflammatory compounds parthenolide and Bay 11-7082 are direct inhibitors of the inflammasome. J Biol Chem. 2010; 285(13): 9792-802.
86. Yin C, Huo F, Zhang J, et al.: Thiol-addition reactions and their applications in thiol recognition. Chem Soc Rev. 2013; 42(14): 6032-59.
87. Santos MM, Moreira R: Michael acceptors as cysteine protease inhibitors. Mini Rev Med Chem. 2007; 7(10): 1040-50.
88. Cocco M, Garella D, Di Stilo A, et al.: Electrophilic warhead-based design of compounds preventing NLRP3 inflammasome-dependent pyroptosis. J Med Chem. 2014; 57(24): 10366-82.
89. Cocco M, Miglio G, Giorgis M, et al.: Design, Synthesis, and Evaluation of Acrylamide Derivatives as Direct NLRP3 Inflammasome Inhibitors. ChemMedChem. 2016.
90. Spitzer KW, Vaughan-Jones RD: Regulation of Intracellular pH in Mammalian Cell. In The Sodium-Hydrogen Exchanger. Springer US, 2003; 1-15.